Cord Blood News 10.48 December 6, 2018 | |
| |
TOP STORYScientists assessed the safety and efficacy of a umbilical cord blood graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft. [J Clin Oncol] Abstract | Press Release | Press Release 2 | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers investigated the discriminative capacity of an augmented comorbidity/age index among 724 recipients of allogeneic hematopoietic cell transplantation from HLA-mismatched, haploidentical, and umbilical cord blood grafts between 2000 and 2013. [Biol Blood Marrow Transplant] Abstract A dual neurovascular injured erectile dysfunction model was established in athymic rats by crushing the bilateral cavernous nerves and ligations of the bilateral internal pudendal nerve‐vessel bundles. At the time of defect creation, three different types of human cell populations, umbilical vein endothelial cells, adipose derived stem cells and amniotic fluid derived stem cells, were injected intracavernously into the penile tissue. [BJU Int] Abstract The authors identified 436 significantly differentially expressed genes between the two cell types, playing roles in processes including immunomodulation, angiogenesis, wound healing, apoptosis, anti-tumour activity, and chemotaxis [Stem Cells Dev] Abstract Using equine cord blood (CB)-MSCs and umbilical cord tissue (CT)-MSCs from the same donor, scientists hypothesized that MSCs from both sources would have a similar immunophenotype, that CB-MSCs would be more amenable to differentiation, and that they can equally suppress lymphocyte proliferation. [Stem Cells Dev] Abstract Researchers demonstrated that all explored DNA methyltransferases and p53 inhibitors initiated cardiomyogenesis‐related alterations in amniotic fluid (AF)‐derived MSCs through rather similar mechanisms but to a different extent providing useful insights for the future research and potential applications of AF‐MSCs. [J Cell Biochem] Abstract Investigators determined whether transplantation of glial cell line-derived neurotrophic factor-modified amniotic fluid-derived stem cells (AFSCs) was more useful than transplantation of unmodified AFSCs for the treatment of renal interstitial fibrosis. [Cell Transplant] Full Article This induced pluripotent stem cell colonies were fully reprogrammed based on SSEA4 expression. A total of 300,000 cord blood-derived mononuclear cells was the optimal cell number for cell reprogramming, which was associated with a 13-fold increase in CD34+ cells upon exposure to HSC media. [Regen Med] Full Article Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSProspect of Mesenchymal Stem Cells in Therapy of Osteoporosis: A Review Scientists summarize the therapeutic role of stem cell-based strategy in osteoporosis. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
SCIENCE NEWSMagenta Therapeutics announced that the company presented initial Phase II clinical data and preclinical research on its MGTA-456 program. MGTA-456 is a cell therapy providing a high dose of hematopoietic stem cells that are well-matched to the patient, administered through a transplant procedure. [Press release from Magenta Therapeutics discussing research presented at the 60th Annual Meeting of the American Society of Hematology (ASH), San Diego] Press Release ExCellThera Announces Results of Clinical Trial Using ECT-001 for Blood Cancers ExCellThera Inc. announced results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic stem cell transplant. The results demonstrated conclusively that blood cells expanded for seven days with ECT-001 are effective at providing substantial clinical benefits when compared to standard of care for bone marrow transplants. [Press release from ExCellThera Inc. discussing research presented at the 60th Annual Meeting of the American Society of Hematology (ASH), San Diego] Press Release | |
| |
INDUSTRY NEWSBlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute BlueRock Therapeutics, LP announced the strengthening of its ongoing strategic collaboration with the McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto. [BlueRock Therapeutics, LP] Press Release Addressing the Sector Skills Gap with First Apprenticeship Program for Advanced Therapies The Cell and Gene Therapy Catapult launched the first Advanced Therapy Medicinal Products (ATMP) focused apprenticeship program developed in partnership with The Medicine Manufacturing Industry Partnership and aimed at building the skills base needed to support the growing UK industry in the development of ATMPs. [The Cell and Gene Therapy Catapult] Press Release | |
| |
POLICY NEWSChina Backs Bold Plan to Tear Down Journal Paywalls In a huge boost to the open-access movement, librarians and funders in China have said that they intend to make results of publicly funded research free to read immediately on publication. The move includes a pledge of support for Plan S, a bold initiative launched in September by a group of European funders to ensure that, by 2020, their scientists make papers immediately open. [Nature News] Editorial Government Loyalist Appointed New UK Science Minister as Brexit Woes Continue Amid the carnage of Brexit, the UK government has gained a new science minister. Chris Skidmore was appointed on 5 December, succeeding Sam Gyimah, who resigned last week over the direction of Brexit negotiations. [Nature News] Editorial Trump Emphasizes Workforce Training in New Vision for Stem Education The U.S. government needs to partner with industry and community organizations to train more Americans for jobs in an increasingly high-tech work environment. That’s the key message in a new 5-year strategic plan for science, technology, engineering, and math (STEM) education released by U.S. President Donald Trump’s administration. [ScienceInsider] Editorial
| |
EVENTSNEW AACR International Conference New Horizons in Cancer Research Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Officer – Hematopoietic Stem Cells (The University of Queensland) Tenure Track Assistant Professor – Center for Regenerative Medicine (Massachusetts General Hospital) Associate Professor/Professor – Regenerative Medicine or Stem Cell Biology (University of Toronto) Postdoctoral Fellowship – Leukemia (Lund University) Research Scientist – Hematologic Malignancies (Mayo Clinic) Process Scientist – Cell Therapy (University College London) Postdoctoral Research Scientist – Hematopoietic Stem Cells (Columbia University Medical Center) Faculty Position – GvHD or Immunotherapy (Medical College of Wisconsin) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|